Global Human Microbiome Market Projected to Cross $1.73 Billion by 2027 - Increased Focus on Human Microbiome Therapy Development Drives Market Growth - ResearchAndMarkets.com

DUBLIN--()--The "Human Microbiome Market by Product (Prebiotic, Probiotic, Food, Medical Food, Drug), Application (Therapeutic), Disease (Infectious, Metabolic/Endocrine, Cancer, Blood, Neurological), Research Technology (Proteomics, Metabolomics) - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

The human microbiome market is projected to reach USD 1,731.3 million by 2027 from USD 364.3 million in 2022, at CAGR of 22.5% from 2024 to 2027.

This market study covers the human microbiome market across various segments. It aims at estimating the market size and the growth potential of this market across different segments, based on the product, application, disease, and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.

The human microbiome market comprises major players such as Enterome Bioscience (France), Seres Therapeutics (US), and 4D Pharma (UK). The study includes an in-depth competitive analysis of these key players in the patient market, along with their company profiles, recent developments, and key market strategies.

Increased focus on human microbiome therapy development to drive the growth of this market.

Market growth is largely driven by the increasing focus on the development of human microbiome therapy. It has also become a validated target for drug development. The growing number of collaborations between market players is expected to offer a wide range of growth opportunities for market players during the forecast period. However, a lack of expertise and detailed research on the human microbiome is restraining the growth of this market.

Prebiotics are expected to grow at the highest CAGR during the forecast period.

Based on product, the human microbiome market is segmented into probiotics, prebiotics, foods, medical foods, diagnostic tests, and drugs. Of these, probiotics are expected to grow at the highest CAGR during the forecast period. The large share of this market segment can primarily be attributed to growing awareness about probiotics as a potential therapy and the credibility of health claims and safety of probiotics.

The diagnostics segment is expected to grow at the highest CAGR during the forecast period.

Based on application, the human microbiome market is segmented into therapeutics and diagnostics. The diagnostics segment is expected to grow at the highest CAGR in the forecast period. Advances in life science research on a wide number of diseases, technological innovations in human genome mapping, the emergence of omics technologies, and the increasing emphasis on improving the cost-effectiveness of healthcare and patient outcomes are some of the major factors driving the growth of this segment.

The infectious diseases segment is expected to grow at the highest CAGR during the forecast period.

The infectious disease segment is expected to account for the largest share of the global human microbiome market in 2024. This is due to increasing research in microbiome-based products and their use in treating infectious diseases. Many smaller companies are investing in research, and their major focus is on developing products targeting the microbiome modulators for infectious diseases, which accounts for 40-50 products that are currently in the pipeline.

The genomics segment is expected to grow at the highest CAGR during the forecast period.

On the basis of technology, the human microbiome research spending market is segmented into genomics, proteomics, and metabolomics. The genomics segment is expected to grow at the highest CAGR during the forecast period. The increasing number of projects funded by private and government bodies is a key driver for the genomics market. Newly emerging disciplines such as metagenomics help researchers to uncover what microorganisms are present in a sample, to determine their relative abundance and gain insights on their biochemical pathways.

North America to grow at the highest CAGR during the forecast period.

In the human microbiome market, North America is estimated to grow at the highest CAGR during the forecast period. Factors such as the increasing incidence of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and growing acceptance of probiotic products are the factors driving the North American human microbiome market.

Key Benefits of Buying the Report

  • The report will help market leaders/new entrants in this market and provide information on the closest approximations of the revenue numbers for the overall human microbiome market and its sub-segments.
  • This report will help the stakeholders to understand the competitive landscape, to gain more insights to better position their businesses, and to plan suitable go-to-market strategies.
  • The report will also help the stakeholders to understand the pulse of the market and provide information on key market drivers, restraints, opportunities, and challenges.

Market Dynamics

Drivers

  • Increased Focus on Human Microbiome Therapy Development
  • Human Microbiome as a Validated Target for Drug Development
  • Human Microbiome for Early Disease Detection & Diagnosis

Restraints

  • Lack of Expertise & Detailed Research
  • Barriers in Proving the Causal Link Between Dysbiosis & Disease

Opportunities

  • Investigational New Drug Requirements for Fecal Microbiota
  • Increasing Collaborations

Challenges

  • Government Regulations

Companies Profiled

  • Enterome Bioscience
  • Seres Therapeutics
  • 4D Pharma PLC
  • Ubiome Inc.
  • E.I. Du Pont De Nemours & Company
  • Synlogic
  • Second Genome
  • Vedanta Biosciences Inc.
  • Ferring Pharmaceuticals
  • Evelo Biosciences Inc.
  • Vithera Pharmaceuticals Inc.
  • Biomx
  • LNC Therapeutics

For more information about this report visit https://www.researchandmarkets.com/r/vay42y

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900